<h4>Background</h4>The anaplastic lymphoma kinase (<i>ALK</i>) mutation, also known as the diamond mutation in non-small-cell lung cancer (NSCLC), has been treated with tremendous success since it was first reported in 2007. Here, ALK is linked to non-small cell lung carcinoma.